Laurie J. Hall Trustee’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.98M Buy
5,990
+30
+0.5% +$13.3K 0.93% 34
2026
Q1
$2.66M Sell
5,960
-70
-1% -$32.6K 0.94% 34
2025
Q4
$2.73M Buy
6,030
+80
+1% +$34.5K 0.91% 38
2025
Q3
$2.33M Buy
5,950
+385
+7% +$161K 0.76% 39
2025
Q2
$2.48M Buy
5,565
+37
+0.7% +$17.1K 0.82% 38
2025
Q1
$2.68M Buy
5,528
+385
+7% +$179K 0.96% 38
2024
Q4
$2.07M Buy
5,143
+383
+8% +$178K 0.68% 44
2024
Q3
$2.21M Buy
4,760
+155
+3% +$74.5K 0.7% 44
2024
Q2
$2.16M Buy
4,605
+20
+0.4% +$8.68K 0.75% 38
2024
Q1
$1.92M Buy
4,585
+4,285
+1,428% +$1.81M 0.68% 42
2023
Q4
$122K Hold
300
0.05% 133
2023
Q3
$104K Hold
300
0.04% 134
2023
Q2
$106K Hold
300
0.04% 139
2023
Q1
$95K Hold
300
0.04% 141
2022
Q4
$87K Hold
300
0.04% 145
2022
Q3
$87K Hold
300
0.04% 141
2022
Q2
$85K Hold
300
0.04% 146
2022
Q1
$78K Hold
300
0.03% 155
2021
Q4
$66K Hold
300
0.02% 177
2021
Q3
$54K Hold
300
0.02% 185
2021
Q2
$60K Hold
300
0.02% 183
2021
Q1
$64K Buy
+300
New +$65.9K 0.02% 185

Other funds holding VRTX

Laurie J. Hall Trustee's VRTX Position: Q2 2026 in Review

Laurie J. Hall Trustee increased its Vertex Pharmaceuticals (VRTX) stake by 0.5% in Q2 2026, buying an estimated $13.3K and bringing the position to 5,990 shares worth $2.98M. The position accounts for 0.93% of the portfolio, ranked #34.

Laurie J. Hall Trustee first reported a position in VRTX in Q1 2021 and has held it in 22 quarters since. 252 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Laurie J. Hall Trustee held 5,990 shares of Vertex Pharmaceuticals worth $2.98M as of Q2 2026.
  • Laurie J. Hall Trustee bought 30 Vertex Pharmaceuticals shares in Q2 2026, an estimated $13.3K.
  • Vertex Pharmaceuticals made up 0.93% of Laurie J. Hall Trustee's portfolio in Q2 2026, its #34 holding.
  • Laurie J. Hall Trustee first reported a position in Vertex Pharmaceuticals in Q1 2021 and has held it in 22 quarters since.
  • 252 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Laurie J. Hall Trustee's 13F filing for Q2 2026, filed 9 Jul 2026.